Condition: Cannabis, Drug Effects · Driving Performance · Sponsor: Food and Drug Administration (FDA)
With the increasing prevalence and use of cannabis products by the public, there exists a need to better understand the safety impact of cannabis use, particularly when it comes to subjective perceptions of drug effect and driving impairment. This study aims to evaluate the dose-dependent effects of oral Δ9-THC alone and in combination with alcohol (0.08% BAC \[Blood Alcohol Concentration\]) on driving performance and subjective feeling in healthy adults. The results of this study will address current knowledge gaps on the effects of oral Δ9-THC on driving impairment across a clinically relevant dose range.
This description comes directly from the study's public registry record.
Trupti Indurkar · 3475740355 · trupti.indurkar@spauldingclinical.com
Karrielyn Gerlach · 9205172167 · karrielyn.gerlach@spauldingclinical.com
Always discuss trial participation with your own doctor first.
| Spaulding Clinical Research | West Bend, Wisconsin, United States | Recruiting |
| Spaulding Clinical | West Bend, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07176208